Feasibility study of Docetaxel plus Bevacizumab in selected patient with previously treated advanced NSCLS(non-squamous).

Feasibility study of Docetaxel plus Bevacizumab in selected patient with previously treated advanced NSCLS(non-squamous). - Feasibility study of Docetaxel plus Bevacizumab in selected patient with previously treated advanced NSCLS(non-squamous).

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003397

Enrollment

Registered

2010-03-29

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Previously treated advanced NSCLC(non-squamous)

Interventions

Bevacizumab plus Docetaxel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients recived one previus platinum-bsed chemotherapy rejimen for NSCLC. Patients with histologically or cytologically confirmed NSCLC were eligible. An ECOG performance status of 0 to 2

Exclusion criteria

Exclusion criteria: Patients with Brain metastasis. Patinets with symptomatic congestive heart failure,unstable angina pectoris,cardiac arrhythmias,thorombotic events,a history of gross hemoptysis.

Design outcomes

Primary

Measure	Time frame
frequency DLT	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026